Respiratory Drugs During Breastfeeding

2019 ◽  
Vol 14 (9) ◽  
pp. 613-615
Author(s):  
Philip O. Anderson
Keyword(s):  
Respiratory Drugs

PSYCHIATRIC EFFECTS PRODUCED BY RESPIRATORY DRUGS

1984 ◽  
Vol 7 ◽  
pp. S489
Author(s):  
R. C.W. Hall ◽  
J. H. Coleman ◽  
T. P. Beresford
Keyword(s):  
Respiratory Drugs

Respiratory drugs

2019 ◽  
pp. 167-176
Author(s):  
Carl Waldmann ◽  
Andrew Rhodes ◽  
Neil Soni ◽  
Jonathan Handy
Keyword(s):  
Nitric Oxide ◽  
Oxygen Therapy ◽  
Patient Monitoring ◽  
Face Mask ◽  
Intermittent Positive Pressure Ventilation ◽  
Inhaled Nitric Oxide ◽  
Positive Pressure ◽  
Anticholinergic Agents ◽  
Oxygen Gas ◽  
Respiratory Drugs

This chapter discusses respiratory drugs and includes discussion on bronchodilators (describing β‎2-agonists, anticholinergic agents, and xanthine derivatives), nitric oxide (history, biochemistry, clinical use of inhaled nitric oxide, administration of inhaled nitric oxide, adverse effects of inhaled nitric oxide, and adjunctive therapies), mucolytics (properties of mucus, types of mucolytics, clinical applications, and side-effects), and helium–oxygen gas mixtures (including nomenclature, rationale, indications, expected effects, presentation, face mask administration, nebulization, patient monitoring during therapy, stopping helium–oxygen therapy, indications for helium–oxygen mask ventilation, indications for helium–oxygen intermittent positive pressure ventilation (IPPV) via endotracheal or tracheostomy tube, patient monitoring during IPPV therapy, stopping helium–oxygen therapy, and published trials).

scholarly journals Dynamics in diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis

2020 ◽  
Vol 6 (4) ◽  
pp. 00479-2020
Author(s):  
Jesper Rømhild Davidsen ◽  
Lars Christian Lund ◽  
Christian B. Laursen ◽  
Jesper Hallas ◽  
Daniel Pilsgaard Henriksen
Keyword(s):  
Drug Use ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Opium Alkaloids ◽  
Before And After ◽  
Oral Corticosteroids ◽  
Drug Treatments ◽  
Respiratory Drugs

BackgroundIdiopathic pulmonary fibrosis (IPF) is a well-characterised interstitial lung disease. Typically, IPF diagnosis is delayed due to nonspecific symptoms, but can also be delayed due to treatment attempts on false indication or due to treatment targeting common comorbidities. This observational study aimed to assess the dynamics in the medication and diagnosis patterns in the period before and after an IPF diagnosis.MethodsWe identified all Danish patients with IPF between 2002 and 2017. We evaluated new and ongoing drug treatments and incident diagnoses 36 months before and 12 months after an IPF diagnosis by use of Danish nationwide registries. To aid interpretation, 10 random controls were recruited for each case.ResultsA total of 650 IPF patients were identified (median age 73 years (interquartile range 65–78), 70.3% males). Prior to the IPF diagnosis, the most prevalent diagnoses were dyspnoea and non-IPF interstitial lung diseases. For drug use, IPF patients had higher initiation rates for antibiotics, oral corticosteroids and mucolytics. In terms of drug volume, IPF patients used more respiratory drugs, antibiotics, immunosuppressants, corticosteroids, proton pump inhibitors, benzodiazepines and opium alkaloids within the 6 months preceding their IPF diagnosis, compared to the controls. Overall drug use decreased after an IPF diagnosis, mainly due to a reduced glucocorticoid and cardiovascular drug use.ConclusionAmong IPF patients, an increased drug use was observed for diagnoses with symptoms overlapping those of IPF, particularly this was observed during the last 6 months before an IPF diagnosis. This emphasises the need for an increased IPF awareness.

Association of human serum paraoxonase‐1 with some respiratory drugs

2019 ◽  
Vol 33 (12) ◽  
Author(s):  
Başak Gökçe ◽  
Nurhan Sarıoğlu ◽  
Nahit Gençer ◽  
Oktay Arslan
Keyword(s):  
Human Serum ◽  
Paraoxonase 1 ◽  
Serum Paraoxonase ◽  
Respiratory Drugs

Regulatory effect of decreasing therapeutic duplication of respiratory drugs using a prescription database between 2012 and 2015

2019 ◽  
Vol 103 ◽  
pp. 218-228
Author(s):  
Hyesung Lee ◽  
Inmyung Song ◽  
Sun Mi Shin ◽  
Han Eol Jeong ◽  
Eui-Kyung Lee ◽  
...  
Keyword(s):  
Prescription Database ◽  
Regulatory Effect ◽  
Therapeutic Duplication ◽  
Respiratory Drugs

scholarly journals Correlates of adherence to respiratory drugs in COPD patients

2010 ◽  
Vol 19 (2) ◽  
pp. 148-154 ◽  
Author(s):  
Laurent Laforest ◽  
Francois Denis ◽  
Eric Van Gansea ◽  
Cecile Ritleng ◽  
Christel Saussier ◽  
...  
Keyword(s):  
Copd Patients ◽  
Respiratory Drugs

Respiratory drugs influence lung mucociliary clearance in central and peripheral ciliated airways

CHEST Journal ◽  
1981 ◽  
Vol 80 (6) ◽  
pp. 877-880 ◽  
Author(s):  
W. Foster ◽  
E. Langenback ◽  
E. Bergofsky
Keyword(s):  
Mucociliary Clearance ◽  
Respiratory Drugs

scholarly journals In Vitroandin SilicoTools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages

2017 ◽  
Vol 14 (4) ◽  
pp. 1033-1046 ◽  
Author(s):  
Ayşe Ufuk ◽  
Frauke Assmus ◽  
Laura Francis ◽  
Jonathan Plumb ◽  
Valeriu Damian ◽  
...  
Keyword(s):  
Cellular Uptake ◽  
Alveolar Macrophages ◽  
Human Alveolar Macrophages ◽  
Respiratory Drugs
Sign in / Sign up

Export Citation Format

Share Document